Nicola J A. Scott, et.al., Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice., American journal of physiology. Endocrinology and metabolism, 2012, 302

http://rdf.ncbi.nlm.nih.gov/pubmed/22185842

Nicola J A. Scott, et.al., Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice., American journal of physiology. Endocrinology and metabolism, 2012, 302

pubmed

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• increased circulating VLDL cholesterol level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0005145I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased circulating tumor necrosis factor level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0008553I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• decreased circulating insulin level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0002727I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased circulating interleukin-6 level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0008596I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• insulin resistance_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0005331I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• abnormal gonadal fat pad morphology_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0005335I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• abnormal circulating cytokine level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0010210I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased circulating triglyceride level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0001552I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• abnormal liver morphology_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0000598I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• abnormal aorta bulb morphology_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0011572I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased fat cell size_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0006094I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• hepatic steatosis_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0002628I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased circulating LDL cholesterol level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0000182I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased circulating cholesterol level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0005178I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased body weight_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0001260I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased liver weight_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0002981I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• hypertension_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0000231I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• decreased circulating HDL cholesterol level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0000186I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• atherosclerotic lesions_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0005338I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• impaired glucose tolerance_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0005293I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased circulating glucose level_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0005559I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc
• increased systemic arterial blood pressure_Apoe<tm1Unc>/Apoe<tm1Unc>,Cyp19a1<tm1Esi>/Cyp19a1<tm1Esi>
  http://metadb.riken.jp/0002842I129P2OlaHsd129S6SvEvTacC57BL6Apoetm1UncApoetm1UncCyp19a1tm1EsiCyp19a1tm1EsiCyp19a1tm1EsiApoetm1Unc